Drug Discovery
Drug Discovery covers where GLP-1 came from and where it’s going. Single-agonist (semaglutide), dual-agonist (tirzepatide), triple-agonist (retatrutide in trials), and oral small-molecule (orforglipron, just approved as Foundayo) — each represents a different bet on maximizing efficacy while managing side effects. We explain mechanisms and track the late-stage pipeline.
Do GLP-1 Drugs Cause Cancer? Honest Answer.
A boxed warning, scary headlines, anxious social-media posts. The real cancer evidence on GLP-1 drugs is more nuanced — and…
Latest in Drug Discovery
GLP-1 in 2026: 5 Big Changes Coming Soon
A new pill, a far more powerful drug in trials, a Medicare pilot, a tightening line on compounding. The GLP-1…
Compounded Semaglutide from $147/month
More from Drug Discovery
Compounded Semaglutide: Are Side Effects Different?
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Compounding Pharmacy: 5 Red Flags to Avoid
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Compounded Tirzepatide (2026): Legal? Worth It?
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Compounded vs Brand GLP-1: Is It Really the Same?
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Compounded Semaglutide: What FDA’s Proposal Means (2026)
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…